Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abated, Allergen, allocated, amortization, amortize, amortized, APB, ASP, awaiting, bad, binding, category, cell, CMS, codevelopment, collateral, component, concentrated, concentration, concert, core, CTI, directly, discount, disposing, disputed, disruption, diversification, employee, escrow, escrowed, eventually, experienced, firm, follicular, front, fully, hope, independent, India, infrastructure, innovative, installment, intangible, Kumaria, lead, leucovorin, low, lymphoma, Medicaid, medical, Medicare, metastatic, methodology, Mumbai, NHL, obsolete, OncoRx, opportunity, originally, overhead, palliative, PDUFA, pension, perspective, pertaining, Pharma, pool, postretirement, prepaid, prepay, prepayment, prolong, Quebec, rapid, recruit, reflected, remove, Restated, return, RIT, sBLA, segment, shalll, shortage, shorter, Shyam, Similarly, sNDA, source, stage, support, survival, sustainable, tender, tendered, tiuxetan, turnover, unamortized, unanticipated, unexercised, unpaid, usage, User, venture, writing, zevalin
Removed:
abbreviated, achieving, acid, advice, announced, benign, Biotech, BPH, carcinoma, comparability, consistently, controlling, counteract, deconsolidated, deconsolidation, deferral, diminish, distinguish, earn, economic, EMEA, equivalent, European, exit, face, February, folic, gain, GPC, health, hypertrophy, identified, impaired, improve, inadvertent, initially, initiated, labeled, laboratory, launch, legal, likelihood, measuring, methotrexate, mix, NDA, NeoJB, orderly, osteosarcoma, overdose, ozarelix, parent, performing, prepare, procedure, progressive, prostatic, protocol, randomized, range, recurrent, reduction, relevance, rescue, retained, Sagent, satraplatin, September, submitted, sufficiency, sumatriptan, tablet, tolerability, toxicity, transfer, transparency, varying, warrant
Filing tables
Filing exhibits
SPPI similar filings
Filing view
External links
EXHIBIT 32.2
Certification
Pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Spectrum Pharmaceuticals, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:
(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2009 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 15, 2009 | /s/ SHYAM K. KUMARIA | |||
Shyam K. Kumaria | ||||
Vice President, Finance |
This certification accompanies the Quarterly Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.